Success Stories

The success of Exscalate

Exscalate is growing. As we grow, our success grows. But it’s not just our success. We share our success with our partners who we collaborate with on various projects. Whether it’s drug discovery projects that are identifying new molecules to address unmet medical needs or technology projects that are advancing future drug discovery platforms with cutting edge technologies, Exscalate is focused on successful outcomes. And ultimately our success will benefit patients who, after all, is the reason why we do it. 

Drug discovery projects

Whether collaborating with pioneering biopharma start-ups or working as part of a consortium of partners, Exscalate’s AI-driven supercomputing platform is helping to rapidly identify effective treatments to address unmet clinical needs.

Technology projects

Exscalate is boosting its drug discovery platform through our involvement in a number of European technology projects. Together with partners, these projects are harnessing the unprecedented power of supercomputing resources together with advances in machine learning and simulation to equip the scientific community with the tools that will enable them to find better cures, faster.

Drug Project

Tech Project

Discover the story of Akash, from Assam to Naples

18th September 2023

The journey of Akash Deep Biswas, from studying in India to working at Dompé's Exscalate laboratory in Naples

Turning collaborative simulations into therapeutic solutions

27th July 2023

Nobel Prize Arieh Warshel among authors of MEDIATE’s results published in Expert Opinion on Drug Discovery

Machine Learning: Binding Affinity prediction and Ligand Pose Selection

26th July 2022

Binding affinity estimation between protein and ligand is an essential part of the drug discovery process. Different approaches have been developed to build functions (empirical, forcefield based, knowledge based and, more recently, machine learning based) to evaluate the binding affinity between the receptor and the possible poses of the ligand generated by the docking algorithms.

HPC and Quantum Computing: Small Molecular Unfolding in Protein Pocket

8th March 2021

Molecular Docking is an important step in the drug discovery process that aims at calculating the location and preferred position and shape of one molecule to a second when they are bound to each other.

Deep-tech project LIGATE

12th September 2020

European project LIGATE is harnessing the revolutionary power of exascale computing together with advances in AI, big data analytics and simulation software to boost Exscalate’s drug discovery platform in identifying effective drugs to tackle unmet medical needs.

Drug repurposing approach to fight Covid-19

1st April 2020

Exscalate4CoV, a public-private consortium of European partners, leveraged the power of Exscalate’s supercomputing AI-driven platform in the fight against COVID-19. In just four months a low molecular weight negative allosteric modulator, Raloxifene, was identified and successfully entered Phase III clinical trials.

Rapidly discovering new compounds for Zika virus

10th April 2019

As part of an ambitious European project, Exscalate’s supercomputing platform was leveraged to support the scientific community in successfully identifying active compounds against Zika virus in a very limited timescale.

Exscalate4Cov is now a book on High-Performance Computing for COVID Drug Discovery

22nd May 2023

Springer's recently published Exscalate4CoV: High-Performance Computing for COVID Drug Discovery opens a window on what can be, and has been done with these new tools right in the middle of the worst pandemic living humans have seen.

“We have developed the world’s first human extracellular matrix (ECM)-based drug discovery platform. The ECM is a key component of human tissues constantly remodelled during disease progression and it acts as common denominator between fibrosis and solid tumours. The use of tissue- and disease-specific human ECM platform is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Exscalate accelerates the pre-clinical and clinical translation of identified targets, helping us not only to quickly identifying hits and candidates molecules for drug discovery and development but to promptly address potential tox risks and off-target selectivity through artificial intelligence and ultra-high performance supercomputing. This strategic partnership is a great example of how the combination of two technology platforms, our human ECM and Exscalate, together with our joint teams’ insights and co-operation, can accelerate research that will bring new therapeutic solutions to unmet patient needs." 

Giuseppe Mazza, Chief Executive Officer and Co-Founder of Engitix

Dompé’s Exscalate platform rapidly accelerated the timeline from target identification to IND for our lead compound A197, a novel immunomodulatory agent. In just 14 months, we received FDA acceptance of our IND application for a new molecular entity (NME) and are now enrolling subjects in a robust Phase 2 clinical trial.

Reza Dana, MD, MPH, MSc - Scientific Co-Founder of Aramis Biosciences and faculty member at Massachusetts Eye and Ear, Harvard Medical School, Boston.

“We have developed the world’s first human extracellular matrix (ECM)-based drug discovery platform. The ECM is a key component of human tissues constantly remodelled during disease progression and it acts as common denominator between fibrosis and solid tumours. The use of tissue- and disease-specific human ECM platform is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Exscalate accelerates the pre-clinical and clinical translation of identified targets, helping us not only to quickly identifying hits and candidates molecules for drug discovery and development but to promptly address potential tox risks and off-target selectivity through artificial intelligence and ultra-high performance supercomputing. This strategic partnership is a great example of how the combination of two technology platforms, our human ECM and Exscalate, together with our joint teams’ insights and co-operation, can accelerate research that will bring new therapeutic solutions to unmet patient needs." 

Giuseppe Mazza, Chief Executive Officer and Co-Founder of Engitix

Dompé’s Exscalate platform rapidly accelerated the timeline from target identification to IND for our lead compound A197, a novel immunomodulatory agent. In just 14 months, we received FDA acceptance of our IND application for a new molecular entity (NME) and are now enrolling subjects in a robust Phase 2 clinical trial.

Reza Dana, MD, MPH, MSc - Scientific Co-Founder of Aramis Biosciences and faculty member at Massachusetts Eye and Ear, Harvard Medical School, Boston.

“We have developed the world’s first human extracellular matrix (ECM)-based drug discovery platform. The ECM is a key component of human tissues constantly remodelled during disease progression and it acts as common denominator between fibrosis and solid tumours. The use of tissue- and disease-specific human ECM platform is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Exscalate accelerates the pre-clinical and clinical translation of identified targets, helping us not only to quickly identifying hits and candidates molecules for drug discovery and development but to promptly address potential tox risks and off-target selectivity through artificial intelligence and ultra-high performance supercomputing. This strategic partnership is a great example of how the combination of two technology platforms, our human ECM and Exscalate, together with our joint teams’ insights and co-operation, can accelerate research that will bring new therapeutic solutions to unmet patient needs." 

Giuseppe Mazza, Chief Executive Officer and Co-Founder of Engitix

Partnerships

We have formed many successful partnerships. Together we are accelerating drug discovery.